Skip to main content

Table 1 Baseline characteristics of patients with IgD MM, LCMM and healthy CTRs

From: N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma

M protein type IgD MM LCMM Healthy CTR
(κ 1, λ 19) (κ 19, λ 22) (n = 42)
Male (%) 12 (60.0%) 26 (63.4%) 25 (59.5%)
Age 56.75 ± 9.51 58.17 ± 12.14 59.14 ± 5.90
ISS stage I 4 (20.0%) 11 (26.8%) /
ISS stage II 5 (25.0%) 3 (7.3%) /
ISS stage III 11 (55.0%) 27 (65.9%) /
Durie Salmon stage IIIA 16 (80.0%) / /
Durie Salmon stage IIIB 4 (20.0%) / /
Haemoglobin 89.50 ± 20.61 100.28 ± 28.46 146.34 ± 9.42
Total protein 62.95 ± 8.83 60.88 ± 7.89 76.24 ± 3.87
Albumin 36.33 ± 4.60 39.23 ± 5.51 47.17 ± 2.18
Serum FLC ratio 2.62 ± 1.74 / /
Urine FLC ratio 204.47 ± 262.98 / /
SPE positive (%) 13 (65.0%) 11 (26.8%) /
IFE positive (%) 18 (90.0%) 23 (56.1%) /
Bone lesions (%) 14 (70.0%) / /
Extramedullary infiltration (%) 3 (15.0%) / /
  1. Note: Quantitative data are expressed as the means ± standard deviation; qualitative data are expressed as n (%);/represents no relevant data documented
  2. Abbreviations: ISS international staging system, SPE serum protein electrophoresis, IFE immunofixation electrophoresis, FLC free light chain (including 15 serum samples and 16 urine samples in patients with IgD MM)